Entries by Press

Fusion Pharma to Present at the EANM 2018 Congress and BIO Investor Forum 2018

BOSTON, MA and HAMILTON, ONTARIO, October 15, 2018 – Fusion Pharmaceuticals, a biopharmaceutical company focused on radiotherapeutics (specifically, targeted alpha therapeutics), will present at two separate conferences this week.   On Tuesday, October 16, 2018, Fusion will present scientific data on its lead program FPI-1434 at the European Association of Nuclear Medicine (EANM) 2018 Congress.  The […]

Fusion Pharmaceutical to Present at the Bloom Burton & Co. Healthcare Investor Conference 2018

BOSTON, MA and HAMILTON, ONTARIO, April 27, 2018 – Fusion Pharmaceuticals, a biopharmaceutical company focused on radiotherapeutics (specifically, targeted alpha therapeutics), announced it will present at the Bloom Burton & Co. Healthcare Investor Conference 2018 in Toronto, Canada. The Fusion team will also participate in one-on-one meetings with industry stakeholders during the conference. Details of the presentation […]

Fusion Pharmaceuticals Licenses Isogenica’s CIS Display Technology

Technology will be used to progress Fusion’s pipeline of targeted alpha therapeutics for the treatment of cancers Cambridge, UK and Hamilton, Canada, 18th April 2018: Isogenica Ltd and Fusion Pharmaceuticals Inc (Fusion) today announced a new licensing agreement that will leverage each other’s strengths in recombinant protein technologies and radiopharmaceutical development. Isogenica is a leader […]

Fusion Pharmaceuticals announces Marc Schwabish, PhD, joins as SVP, Business Development and US Operations 

BOSTON, MA and HAMILTON, ONTARIO, February 21, 2018 – Fusion Pharmaceuticals, a biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced it has appointed Marc Schwabish, PhD, as Senior Vice President, Business Development and US Operations. Dr. Schwabish will lead a range of activities including licensing, partnering, commercialization, and financing activities. Dr. Schwabish joins from […]

Life Sciences Ontario Announces Recipients of 2018 LSO Awards

TORONTO– LSO today announced the recipients of its 2018 LSO Awards, recognizing outstanding individuals and companies contributing to the success of Ontario’s life sciences sector. The awards will be presented during LSO’s Celebration of Success Awards Dinner at Toronto’s Liberty Grand, February 28, 2018. The 2018 awardees are as follows: Lifetime Achievement Award: Ilse Treurnicht, […]

Fusion Pharmaceuticals Completes Oversubscribed Series A Financing Totaling $46 Million USD to Develop Targeted Alpha Therapeutics

HAMILTON, ONTARIO, September 25, 2017 – Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced it has completed a second closing of its Series A financing, securing an additional $21 million USD in capital and bringing the total capital raised to $46 million USD. New investors in the second […]

Fusion Pharmaceuticals Launches with a $25M USD Series A Financing to Develop Targeted Radiotherapeutics as Cancer Treatments

HAMILTON ONTARIO, February 23, 2017 – Fusion Pharmaceuticals, a newly formed biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the closing of a $25 million Series A financing led by founding venture investor, Johnson & Johnson Innovation – JJDC, Inc., with investments by HealthCap, TPG Biotech, Genesys Capital and FACIT (Fight Against […]

FACIT Announces Investment in Fusion Pharmaceuticals and Alpha-Emitting Radiotherapeutics

Image-guided medicines for hard to treat cancers built using next generation medical isotopes TORONTO, ON (December 16, 2015) – FACIT and Fusion Pharmaceuticals (“Fusion”) announced today an investment to support the development of Fusion’s radiopharmaceutical FPX-01 for the treatment of cancer. Fusion’s drug candidate leverages the potent cell-killing potential of alpha particle-emitting medical isotopes, with […]